| Deregulation of HLA-I in cancer and its central importance for immunotherapy A Hazini, K Fisher, L Seymour Journal for immunotherapy of cancer 9 (8), 2021 | 109 | 2021 |
| Investigation of ischemia modified albumin, oxidant and antioxidant markers in acute myocardial infarction A Hazini, M Cemek, İ Işıldak, S Alpdağtaş, A Önül, Ü Şenel, T Kocaman, ... Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej …, 2015 | 40 | 2015 |
| Effects of food color additives on antioxidant functions and bioelement contents of liver, kidney and brain tissues in rats M Cemek, ME Büyükokuroğlu, F Sertkaya, S Alpdağtaş, A Hazini, A Önül, ... J Food Nutr Res 2 (10), 686-91, 2014 | 40 | 2014 |
| Prevention of cyclophosphamide-induced hemorrhagic cystitis by resveratrol: a comparative experimental study with mesna I Keles, MF Bozkurt, M Cemek, M Karalar, A Hazini, S Alpdagtas, H Keles, ... International urology and nephrology 46, 2301-2310, 2014 | 37 | 2014 |
| Coxsackievirus B3—its potential as an oncolytic virus A Geisler, A Hazini, L Heimann, J Kurreck, H Fechner Viruses 13 (5), 718, 2021 | 30 | 2021 |
| Heparan sulfate binding coxsackievirus B3 strain PD: A novel avirulent oncolytic agent against human colorectal carcinoma A Hazini, M Pryshliak, V Brueckner, K Klingel, M Sauter, S Pinkert, ... Human Gene Therapy 29 (11), 1301-1314, 2018 | 28 | 2018 |
| Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas S Pinkert, M Pryshliak, K Pappritz, K Knoch, A Hazini, B Dieringer, ... Cardiovascular Research 116 (10), 1756-1766, 2020 | 26 | 2020 |
| miR-375-and miR-1-regulated coxsackievirus B3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas A Hazini, B Dieringer, M Pryshliak, KP Knoch, L Heimann, B Tolksdorf, ... Human Gene Therapy 32 (3-4), 216-230, 2021 | 21 | 2021 |
| MiR‐375‐mediated suppression of engineered coxsackievirus B3 in pancreatic cells M Pryshliak, A Hazini, K Knoch, B Dieringer, B Tolksdorf, M Solimena, ... FEBS letters 594 (4), 763-775, 2020 | 16 | 2020 |
| Tackling HLA deficiencies head on with oncolytic viruses K Fisher, A Hazini, LW Seymour Cancers 13 (4), 719, 2021 | 8 | 2021 |
| Application route and immune status of the host determine safety and oncolytic activity of oncolytic coxsackievirus B3 variant PD-H A Hazini, B Dieringer, K Klingel, M Pryshliak, A Geisler, D Kobelt, ... Viruses 13 (10), 1918, 2021 | 6 | 2021 |
| Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis B Tolksdorf, S Zarif, J Eberle, A Hazini, B Dieringer, F Jönsson, F Kreppel, ... Journal of Molecular Medicine 99 (9), 1279-1291, 2021 | 3 | 2021 |
| New postmortem diagnostic biomarker for myocardial infarction: ischemia modified albumin F Yağmur, S Çelik, M Cemek, A Hazini, AT Kocaman, S Alpdoğtaş, ... Australian Journal of Forensic Sciences 51 (2), 191-200, 2019 | 3 | 2019 |
| Coxsackievirus B3—Its Potential as an Oncolytic Virus. Viruses 2021, 13, 718 A Geisler, A Hazini, L Heimann, J Kurreck, H Fechner s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 1 | 2021 |
| Generation of a microRNA-Regulated Oncolytic Coxsackievirus B3 B Dieringer, L Elsner, A Hazini, J Kurreck, H Fechner Gene Therapy of Cancer: Methods and Protocols, 259-282, 2022 | | 2022 |
| miR-375-and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas (vol 32, pg 216, 2021) A Hazini, B Dieringer, M Pryshliak, KP Knoch, L Heimann, B Tolksdorf, ... HUMAN GENE THERAPY 32 (3-4), 231-231, 2021 | | 2021 |
| Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H. Viruses 2021, 13, 1918 A Hazini, B Dieringer, K Klingel, M Pryshliak, A Geisler, D Kobelt, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
| Tackling HLA Deficiencies Head on with Oncolytic Viruses. Cancers 2021, 13, 719 K Fisher, A Hazini, LW Seymour Oncolytic Virus Immunotherapy, 283, 2021 | | 2021 |
| Method for treating cancer with a Coxsackievirus B3 (CVB3) variant H Fechner, A Hazini, V Brueckner US Patent 10,639,337, 2020 | | 2020 |
| MicroRNA-regulated oncolytic coxsackievirus B3 against colorectal carcinoma A Hazini, M Pryshliak, S Pinkert, J Kurreck, H Fechner HUMAN GENE THERAPY 28 (12), A23-A23, 2017 | | 2017 |
